These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 12504552)

  • 1. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.
    Subbarao K; Chen H; Swayne D; Mingay L; Fodor E; Brownlee G; Xu X; Lu X; Katz J; Cox N; Matsuoka Y
    Virology; 2003 Jan; 305(1):192-200. PubMed ID: 12504552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses.
    Kandeil A; Moatasim Y; Gomaa MR; Shehata MM; El-Shesheny R; Barakat A; Webby RJ; Ali MA; Kayali G
    Vaccine; 2016 Jan; 34(2):218-224. PubMed ID: 26620838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
    Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
    Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells.
    Legastelois I; Garcia-Sastre A; Palese P; Tumpey TM; Maines TR; Katz JM; Vogel FR; Moste C
    Influenza Other Respir Viruses; 2007 May; 1(3):95-104. PubMed ID: 19453414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content.
    Abt M; de Jonge J; Laue M; Wolff T
    Vaccine; 2011 Jul; 29(32):5153-62. PubMed ID: 21624413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and evaluation of an Influenza virus subtype H7N2 vaccine candidate for pandemic preparedness.
    Pappas C; Matsuoka Y; Swayne DE; Donis RO
    Clin Vaccine Immunol; 2007 Nov; 14(11):1425-32. PubMed ID: 17913860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
    Suguitan AL; McAuliffe J; Mills KL; Jin H; Duke G; Lu B; Luke CJ; Murphy B; Swayne DE; Kemble G; Subbarao K
    PLoS Med; 2006 Sep; 3(9):e360. PubMed ID: 16968127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A two dose immunization with an inactivated reassortant H5N2 virus protects chickens against lethal challenge with homologous 2.3.2.1 clade and heterologous 2.2 clade highly pathogenic avian influenza H5N1 viruses.
    Bhat S; Sood R; Shukla S; Khandia R; Pateriya AK; Kumar N; Singh VK; Kalaiyarasu S; Kumar M; Bhatia S
    Vet Microbiol; 2018 Apr; 217():149-157. PubMed ID: 29615248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody titer has positive predictive value for vaccine protection against challenge with natural antigenic-drift variants of H5N1 high-pathogenicity avian influenza viruses from Indonesia.
    Swayne DE; Suarez DL; Spackman E; Jadhao S; Dauphin G; Kim-Torchetti M; McGrane J; Weaver J; Daniels P; Wong F; Selleck P; Wiyono A; Indriani R; Yupiana Y; Sawitri Siregar E; Prajitno T; Smith D; Fouchier R
    J Virol; 2015 Apr; 89(7):3746-62. PubMed ID: 25609805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a high-yield attenuated vaccine strain wholly derived from avian influenza viruses by use of reverse genetics.
    Liu M; Liu CG; Zhang Y; Shi WL; Wang W; Liu YY
    Vet Microbiol; 2012 Dec; 161(1-2):43-8. PubMed ID: 22832374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics.
    Tian G; Zhang S; Li Y; Bu Z; Liu P; Zhou J; Li C; Shi J; Yu K; Chen H
    Virology; 2005 Oct; 341(1):153-62. PubMed ID: 16084554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate.
    Chen H; Subbarao K; Swayne D; Chen Q; Lu X; Katz J; Cox N; Matsuoka Y
    Vaccine; 2003 May; 21(17-18):1974-9. PubMed ID: 12706686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadening the H5N3 Vaccine Immunogenicity against H5N1 Virus by Modification of Neutralizing Epitopes.
    Rajesh Kumar S; Chelvaretnam S; Tan Y; Prabakaran M
    Viruses; 2017 Dec; 10(1):. PubMed ID: 29295514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.
    Joseph T; McAuliffe J; Lu B; Vogel L; Swayne D; Jin H; Kemble G; Subbarao K
    Virology; 2008 Aug; 378(1):123-32. PubMed ID: 18585748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat.
    Whiteley A; Major D; Legastelois I; Campitelli L; Donatelli I; Thompson CI; Zambon MC; Wood JM; Barclay WS
    Influenza Other Respir Viruses; 2007 Jul; 1(4):157-66. PubMed ID: 19432631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.